The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients

scientific article published on 31 October 2012

The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1586/ERI.12.114
P698PubMed publication ID23113664

P2093author name stringAndy I M Hoepelman
Annemarie M J Wensing
Steven F L van Lelyveld
P2860cites workEfficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.Q44533053
Transmission of drug-resistant HIV-1 is stabilizing in EuropeQ44591236
Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapyQ45853423
Phenotypic expressions of CCR5-delta32/delta32 homozygosityQ45863096
The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapy.Q53779598
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individualsQ22242705
Identification of a major co-receptor for primary isolates of HIV-1Q22251282
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesQ24597052
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)Q24641929
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study InvestigatorsQ29547281
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infectionQ29614956
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) studyQ33521080
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism studyQ34045403
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activityQ34123595
HIV Infection, Inflammation, Immunosenescence, and AgingQ34150710
Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general populationQ34547175
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infectionQ34597895
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.Q34607511
HIV entry inhibitors.Q34654433
Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemicQ34733732
Maraviroc for previously treated patients with R5 HIV-1 infectionQ34806062
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropismQ35635933
Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.Q35875096
Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practiceQ35959156
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaborationQ37208045
CCR5 antagonism in HIV infection: ways, effects, and side effectsQ37590614
Definition and epidemiology of late presentation in EuropeQ37742324
Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infectionQ37762248
European guidelines on the clinical management of HIV-1 tropism testingQ37856554
Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patientsQ39443078
Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211Q39495730
HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitroQ39501136
Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patientQ39502552
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.Q41557849
Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patientsQ41991922
Correlates of lending needles/syringes among HIV-seropositive injection drug usersQ42640169
Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studiesQ42926976
Long-term immunovirogical effect and tolerability of a maraviroc-containing regimen in routine clinical practiceQ42966027
Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experienceQ43162451
P433issue11
P921main subjectanti-retroviral agentQ50430310
P304page(s)1241-1247
P577publication date2012-10-31
P1433published inExpert Review of Anti-infective TherapyQ15734432
P1476titleThe MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients
P478volume10

Reverse relations

cites work (P2860)
Q38803127CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV.
Q30364312Developments in HIV-1 immunotherapy and therapeutic vaccination.
Q92856694Entanglement of CCR5 and Alzheimer's Disease
Q53707006High Virologic Failure Rates with Maraviroc-Based Salvage Regimens Among Indian Patients: A Preliminary Analysis-Maraviroc Effectiveness in HIV-1 Subtype C.

Search more.